Eckert & Ziegler Announces Clinical Trial Notification for Joint Clinical Trial in Japan

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Study
12.11.2021 / 09:29
The issuer is solely responsible for the content of this announcement.

Berlin, 12 November 2021. Eckert & Ziegler (ISIN DE0005659700, TecDAX) announced that the Clinical Trial Notification (CTN) of a joint clinical study with Novartis Pharma K.K. (Japan) was accepted by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for ⁶⁸Ga-PSMA-11, an investigational radioligand imaging agent and ¹⁷⁷Lu-PSMA-617, an investigational radioligand therapy in metastatic prostate cancer.

Eckert & Ziegler Radiopharma GmbH is manufacturer of the pharmaceutical ⁶⁸Ge/⁶⁸Ga generator GalliaPharm^(R), which is used to produce the radiopharmaceutical ⁶⁸Ga-PSMA-11 for ⁶⁸Ga PET/CT diagnostics. This diagnostic procedure may be used to detect the presence of prostate-specific membrane antigen (PSMA) on prostate cancer cells, enabling localization of tumors.

"The start of this clinical trial is another milestone in our strategy and demonstrates our expertise as an isotope service provider to the global pharmaceutical industry," explains Dr Lutz Helmke, Executive Director and responsible for the Medical segment of Eckert & Ziegler.

PSMA is found in high concentration on the surface of prostate cancer cells, making it a potentially effective target for imaging. Investigational imaging agent ⁶⁸Ga-PSMA-11 has been shown to bind selectively to the PSMA receptor, allowing localization of prostate carcinoma. The same principle may also be used for therapy. In this case, PSMA-617 is attached to the therapeutic radioisotope ¹⁷⁷Lu.

Prostate cancer is the most common cancer among males in Japan, with over 106,000 cases in 2020, a significantly higher incidence than stomach cancer (95,000 new cases) or lung cancer (94,500 new cases) (IARC Global Cancer Observatory, 2020).

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

12.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de